Business Context and Reporting Period
This Form 8-K is a current report filed by AIT Therapeutics, Inc. (a Delaware corporation) on January 31, 2017, regarding events occurring on January 26, 2017. The filing discloses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation:
- Annual Salary: 420,000 New Israeli Shekels (NIS), approximately $113,400 USD (based on an exchange rate of $0.27 per NIS).
- Equity Grant: Options to purchase 50,000 shares of common stock, subject to Board adoption of an equity compensation plan.
Material Changes
The primary material change reported is the appointment of Mr. Hai Aviv as Chief Financial Officer. The filing notes a discrepancy in the text regarding the effective date, stating the appointment was made on January 26, 2017, but effective as of February 27, 2016, while the attached employment agreement exhibit is dated February 28, 2017. Mr. Aviv joins from Babylon Ltd., where he served as CFO from 2013 to the present.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future business performance. The employment agreement includes customary non-disclosure and non-competition covenants. Termination of the agreement by either party requires 90 days' prior written notice. The filing confirms no material transactions involving Mr. Aviv exceeding $120,000 have occurred since the beginning of the last fiscal year.
Investor Verification Checklist
- Verify the correct effective date of Mr. Aviv's appointment given the conflicting dates in the text (Feb 27, 2016) versus the exhibit (Feb 28, 2017).
- Confirm the status of the Board's adoption of the equity compensation plan required to authorize the 50,000 share option grant.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific details on severance and disability benefits beyond the general reference to Israeli law.